





To the Editor: The past 2 decades 
have heralded notable success in efforts 
to control sleeping sickness (human 
African trypanosomiasis [HAT]) in 
Africa. HAT is a neglected tropical 
disease with major public health and 
economic effects in sub-Saharan Africa, 
and its effects on livestock productivity 
and development are considered major 
constraints to alleviating poverty in this 
region (1,2). Because of concerted and 
coordinated continental control efforts, 
its incidence has steadily decreased.
Despite these successes, concern 
has increased recently regarding 
potential convergence of the 2 
causes of HAT (Trypanosoma brucei 
gambiense and T. brucei rhodesiense). 
These organisms differ in transmission 
and how infections are diagnosed and 
treated, and control, and have never 
coincided in the same area. Uganda 
is the only country with endemic 
distributions of these 2 trypanosome 
species, and convergence there 
represents a major public health 
concern, given the potential for 
overlapping infections to compromise 
treatment and control programs and 
spread into neighboring countries (3,4).
Risk for convergence led to an 
international emergency intervention. 
In 2006, an international public–
private partnership, Stamp Out 
Sleeping Sickness (SOS), was 
established to control spread of 
this disease in central Uganda (5). 
However, despite the continental 
effect of convergence of the 2 causes 
of HAT, little is known about trends in 
incidence and epidemiology of HAT 
in central Uganda. We report results of 
data analysis for HAT caused by T. b. 
rhodesiense during 2000–2009.
This study was approved by 
the ethics review board for human 
subjects at McGill University 
(Montreal. Quebec, Canada). We 
obtained data on case-patients given 
a diagnosis of T. b. rhodesiense HAT 
at a HAT treatment unit in Uganda. 
These diagnoses were reported to the 
National Sleeping Sickness Control 
Program of the Ministry of Health 
(4,6). Data were assigned locations 
by parish, and analyses focused 
on spatiotemporal trends in case 
occurrence. The fi nal cleaned dataset 
contained 2,501 reported cases of 
presumed T. b. rhodesiense HAT.
In the past 10 years in Uganda, 
140 cases of fatal T. b. rhodesiense 
HAT have been reported. However, 
given estimates of underreporting and 
cessation of active surveillance, actual 
deaths are likely > 1,700 (170 deaths/
year) (6). Notably, mortality rates 
have increased from an average of 5% 
in the early 2000s to ≈10% in later 
years, and rates have been higher in 
recently affected districts. This pattern 
is predominantly driven by higher 
mortality rates in newly affected 
SOS districts in central Uganda, 
in which diagnostic and treatment 
delays are higher, and from which an 
increasing proportion of HAT cases 
are originating.
Patients in SOS intervention 
districts were more likely to report 
cases in late stages of the disease 
(p<0.01, by χ2 test). The mortality rate 
was >3-fold higher for persons with 
late-stage cases (8.1%) than for those 
with early-stage cases (2.4%) (p<0.01, 
by χ2 test). Given that central Uganda 
is the critical zone for convergence 
and intervention, such evidence of 
presumed diagnosis and treatment 
delay is cause for concern.
The SOS phase 1 intervention 
period (2006–2008) coincided with 
a period of reduced reported pre-
valence of HAT (Figure). The monthly 
average was 27 cases/month before 
the intervention and 10 cases/month 
after the intervention (p<0.01, by 
Mann-Whitney test). However, a 
substantive component of reduction 
in incidence occurred in districts not 
included in the SOS intervention 
program. This pattern may refl ect 
reporting bias caused by a transition 
in Uganda in 2005 to a period of 
passive surveillance and underfunding 
for national reporting. Therefore, 
it remains unclear to what extent 
increased international attention and 
SOS intervention have contributed 
to HAT prevention and control. The 
absence of a clear increase in incidence 
after reinstatement of national data 
acquisition in 2008 provides an early 
indication that interventions may be 
contributing to the decrease in, or at 
least to stabilization of, geographic 
spread in central Uganda.
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Figure. Human African trypanosomiasis cases and deaths by month, Uganda, 2000–2009. 
Bars indicate cases in districts in the Stamp Out Sleeping Sickness (SOS) intervention 
region and outside the SOS region. Solid line indicates overall 24-month moving average 
of deaths, dashed line indicates 24-month moving average of deaths in SOS intervention 
districts, and dotted line indicates 24-month moving average of deaths in non-SOS districts. 
ISCTRC, International Scientifi c Council for Trypanosomiasis Research and Control; J M M 
J S N, Jan, Mar, May, Jul, Sep, Nov.
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HAT data indicate seasonality 
of this disease; incidence is higher 
during January, February, and March 
(p = 0.04, by Mann-Whitney test). 
Seasonality of HAT incidence has 
been noted elsewhere and linked 
to seasonal infl uences on tsetse 
habitat suitability. We propose that 
seasonality of cattle trading may also 
play a role because cattle purchases 
increase before the Christmas season, 
which promote pathogen spread and 
increased transmission. This fi nding is 
consistent with research highlighting 
the role of livestock markets in the 
spread of T. b. rhodesiense in central 
Uganda and would further support 
a body of literature suggesting, as 
espoused by the SOS initiative, 
that control of animal reservoirs of 
the disease is a critical component 
of intervention measures (2,7–9). 
Implementation and enforcement of 
regulations for treatment of cattle 
before sale at markets would also 
contribute to limiting spread (9,10);
Interventions in districts in 
central Uganda in which convergence 
is predicted have been slow and 
incomplete. If convergence has 
occurred, this fi nding indicates 
that a specifi c region in Africa has 
had concurrent infection with both 
causes of HAT, with implications 
for prevention, treatment, and 
control. Since 2000, Uganda has had 
continued northward spread of T. b. 
rhodesiense infections, reducing the 
distance with TbG to <100 km, which 
we believe is a conservative estimate. 
Reinstatement of active surveillance 
of HAT and support for central data 
collection in Uganda are long overdo 
and warranted immediately.
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To the Editor: Rickettsia felis, an 
emerging pathogen fi rst identifi ed in 
the cat fl ea (1), has been detected in 
other fl eas, ticks, mites, and booklice 
(2). R. felis can be cultured in mosquito 
cell lines derived from Anopheles 
gambiae and Aedes albopictus 
(Asian tiger) mosquitoes (2), so 
its compatibility with mosquitoes 
in nature can be suspected. In sub-
Saharan Africa, R. felis bacteremia in 
humans is common¸ especially during 
the rainy season, when mosquitoes 
proliferate. We tested anthropophilic 
mosquitoes for the presence of R. felis 
DNA (3–5).
During December 2008–January 
2010, we randomly selected female Ae. 
albopictus and Ae. aegypti mosquitoes 
(96 each) from specimens obtained by 
human-landing collections from 4 sites 
in Libreville, Gabon (6). Specimens 
were collected during the rainy season 
(mid-January–end of May and end of 
September–mid-December); no parity 
data were available. 
We extracted 192 DNA samples 
from homogenate (abdomen, wings, 
legs) of each nonengorged, host-
seeking, adult mosquito by using 
the BioRobot 8000 (QIAGEN 
S.A.S., Courtaboeuf, France) and 
QIAamp Media MDx Kit (QIAGEN) 
according to the manufacturer’s 
instructions. Samples were screened 
by quantitative real-time PCR 
(qPCR) targeting the biotin synthase 
(bioB) gene (4). Positive results were 
confi rmed by qPCR-based molecular 
detection targeting the orfB gene, 
which codes for a transposition 
helper protein. This qPCR used a 
set of primers not previously used 
in our laboratory (R_fel.OrfB_F:
5′-CCCTTTTCGTAACGCTTTGCT-
3′ and R_fel.OrfB_R: 5′-GGGCTAAA
CCAGGGAAACCT-3′) and the probe 
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